Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Lifetime risk is an epidemiologic measure that expresses the probability of disease in the remaining lifetime for an index age. It is also an easily understandable statistical measure used to communicate the absolute risk of disease to the lay population. The lifetime risk of end-stage kidney disease (ESKD) has never been reported for the Japanese population. Here, we used data from the Japanese Society of Dialysis Therapy (JSDT) to estimate the lifetime risk of ESKD by sex in Japan.
The lifetime risk of ESKD was estimated using life-table methods. We defined an incident case of ESKD as a patient with loss of kidney function that resulted in maintenance dialysis therapy. The number of incident cases of ESKD and number of ESKD deaths in 2017 were obtained from data published by the JSDT. The population and total number of deaths in Japan for the same year were obtained from National Vital Statistics. By including all-cause mortality, risks were adjusted for competing causes of death.
The cumulative incidence of ESKD from birth until age 95 years was 3.14% [95% confidence interval (CI) 3.10–3.18] for men and 1.42% (1.39–1.44) for women. These probabilities illustrate that approximately 1 in 32 men and 1 in 71 women in Japan will develop ESKD that results in maintenance dialysis therapy in their lifetime.
Considerable sex differences were found in the lifetime risk of ESKD in Japan. This easily understandable information could be used to assist in public health education and planning.
Wakasugi M, Kawamura K, Yamamoto S, Kazama JJ, Narita I. High mortality rate of infectious diseases in dialysis patients: a comparison with the general population in Japan. Ther Apher Dial. 2012;16(3):226–31. CrossRef
Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K, Narita I. Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial. 2013;17(3):298–304. CrossRef
Wakasugi M, Matsuo K, Kazama JJ, Narita I. Higher mortality due to intracerebral hemorrhage in dialysis patients: a comparison with the general population in Japan. Ther Apher Dial. 2015;19(1):45–9. CrossRef
Wakasugi M, Kazama JJ, Narita I. Mortality trends among Japanese dialysis patients, 1988–2013: a joinpoint regression analysis. Nephrol Dial Transplant. 2016;31(9):1501–7. CrossRef
Yamagata K, Yagisawa T, Nakai S, Nakayama M, Imai E, Hattori M, et al. Prevalence and incidence of chronic kidney disease stage G5 in Japan: clinical and experimental nephrology. Clin Exp Nephrol. 2015;19(1):54–64. CrossRef
An overview of regular dialysis treatment in Japan as of Dec. 31, 2017 CD‐ROM. Tokyo, Japan: Japanese Society for Dialysis Therapy, 2019
Wakasugi M, Kazama JJ, Narita I. Anticipated increase in the number of patients who require dialysis treatment among the aging population of Japan. Ther Apher Dial. 2015;19(3):201–6. CrossRef
Fay MP. Estimating age conditional probability of developing disease from surveillance data. Popul Health Metrics. 2004;2(1):6. CrossRef
Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ. Age-conditional probabilities of developing cancer. Stat Med. 2003;22(11):1837–48. CrossRef
Institute NC. DevCan—probability of developing or dying of cancer. 2016. https://surveillance.cancer.gov/devcan/. Accessed 8 Nov 2016.
Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James M, et al. Lifetime risk of ESRD. J Am Soc Nephrol. 2012;23(9):1569–78. CrossRef
van den Brand JA, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, et al. Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2017;32(2):348–55. PubMed
Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States. Am J Kidney Dis. 2016;68(6):862–72. CrossRef
United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: National Institutes of Health; 2018.
Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151–64. CrossRef
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82. CrossRef
Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T. Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol. 2008;38(8):571–6. CrossRef
Taniyama Y, Katanoda K, Charvat H, Hori M, Ohno Y, Sasazuki S, et al. Estimation of lifetime cumulative incidence and mortality risk of gastric cancer. Jpn J Clin Oncol. 2017;47(11):1097–102. CrossRef
Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, et al. Lifetime risk of acute myocardial infarction in Japan. Circ Cardiovasc Qual Outcomes. 2010;3(6):701–3. CrossRef
Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M, et al. Lifetime risk of stroke in Japan. Stroke. 2010;41(7):1552–4. CrossRef
- Lifetime and age-conditional risk estimates of end-stage kidney disease requiring maintenance dialysis in Japan
- Springer Singapore
Clinical and Experimental Nephrology
Official Publication of the Japanese Society of Nephrology
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II